BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kang M, Park C, Kim SH, Yoon SW, Suh KJ, Kim YJ, Ock CY, Kim M, Keam B, Kim TM, Kim DW, Heo DS, Lee JS. Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma. Transl Lung Cancer Res 2021;10:699-711. [PMID: 33718015 DOI: 10.21037/tlcr-20-893] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hibino M, Hiranuma O, Takemura Y, Katayama Y, Chihara Y, Harada T, Fujita K, Kita T, Tamiya N, Tsuda T, Shiotsu S, Tamura Y, Aoyama T, Nakamura Y, Terashima M, Morimoto Y, Nagata K, Yoshimura K, Uchino J, Takayama K. Osimertinib and Bevacizumab Cotreatment for Untreated EGFR-Mutated NSCLC With Malignant Pleural or Pericardial Effusion (SPIRAL II): A Single-Arm, Open-Label, Phase 2 Clinical Trial. JTO Clinical and Research Reports 2022;3:100424. [DOI: 10.1016/j.jtocrr.2022.100424] [Reference Citation Analysis]
2 Saw SP, Ng WP, Zhou S, Lai GG, Tan AC, Ang M, Lim W, Kanesvaran R, Ng QS, Jain A, Tan WL, Rajasekaran T, Chan JW, Teh YL, Pang M, Yeo J, Takano A, Ong B, Tan E, Tan SH, Skanderup AJ, Tan DS. PD-L1 score as a prognostic biomarker in Asian early-stage EGFR-mutated lung cancer. European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.10.012] [Reference Citation Analysis]
3 Teranishi S, Sugimoto C, Nagaoka S, Nagayama H, Segawa W, Miyasaka A, Hiro S, Kajita Y, Maeda C, Kobayashi N, Yamamoto M, Kudo M, Kaneko T. Retrospective analysis of independent predictors of progression‐free survival in patients with EGFR mutation‐positive advanced non‐small cell lung cancer receiving first‐line osimertinib. Thoracic Cancer. [DOI: 10.1111/1759-7714.14608] [Reference Citation Analysis]
4 Hsu KH, Tseng JS, Yang TY, Chen KC, Su KY, Yu SL, Chen JJW, Huang YH, Chang GC. PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment naïve advanced EGFR-mutant non-small cell lung cancer patients. Sci Rep 2022;12:9753. [PMID: 35697720 DOI: 10.1038/s41598-022-13102-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wang S, Wang Y, Huang Z, Wei H, Wang X, Shen R, Lan W, Zhong G, Lin J. Stattic sensitizes osteosarcoma cells to epidermal growth factor receptor inhibitors via blocking the interleukin 6-induced STAT3 pathway. Acta Biochim Biophys Sin (Shanghai) 2021;53:1670-80. [PMID: 34693451 DOI: 10.1093/abbs/gmab146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
6 Hellyer JA, White MN, Gardner RM, Cunanan K, Padda SK, Das M, Ramchandran K, Neal JW, Wakelee HA. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer. Clin Lung Cancer 2021:S1525-7304(21)00245-X. [PMID: 34838441 DOI: 10.1016/j.cllc.2021.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Sahu SS, Cavallaro S, Hååg P, Nagy Á, Karlström AE, Lewensohn R, Viktorsson K, Linnros J, Dev A. Exploiting Electrostatic Interaction for Highly Sensitive Detection of Tumor-Derived Extracellular Vesicles by an Electrokinetic Sensor. ACS Appl Mater Interfaces 2021;13:42513-21. [PMID: 34473477 DOI: 10.1021/acsami.1c13192] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]